Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Laurence Booth, Jane L. Roberts, Sarah Spiegel, Andrew Poklepovic & Paul Dent. (2019) Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition. Cancer Biology & Therapy 20:5, pages 597-607.
Read now
Read now
Lingaku Lee, Tetsuhide Ito & Robert T. Jensen. (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opinion on Pharmacotherapy 19:8, pages 909-928.
Read now
Read now
Articles from other publishers (19)
Xianguo Li, Zuojie Peng, Ke An, Mengjiao Xue, Zhenzhen Wang, Junjie Xia, Zhongquan Qi & Xiaogang Shu. (2023) Temsirolimus is a promising immunomodulatory agent for enhanced transplantation outcomes. Transplant Immunology 81, pages 101952.
Crossref
Crossref
Lisa Mayr, Tobias Steinmaurer, Lukas Weseslindtner, Sibylle Madlener, Robert Strassl, Johannes Gojo, Amedeo A. Azizi, Irene Slavc & Andreas Peyrl. (2023) Reply to: Comment on: Viral infections in pediatric brain tumor patients treated with targeted therapies. Pediatric Blood & Cancer 70:9.
Crossref
Crossref
Xian Liu, Xinyu Xiao, Xue Han, Lan Yao & Wei Lan. (2023) Natural flavonoids alleviate glioblastoma multiforme by regulating long non-coding RNA. Biomedicine & Pharmacotherapy 161, pages 114477.
Crossref
Crossref
Lisa Mayr, Tobias Steinmaurer, Lukas Weseslindtner, Sibylle Madlener, Robert Strassl, Johannes Gojo, Amedeo A. Azizi, Irene Slavc & Andreas Peyrl. (2023) Reply to: Comment on: Viral infections in pediatric brain tumor patients treated with targeted therapies. Pediatric Blood & Cancer 70:5.
Crossref
Crossref
Lisa Mayr, Tobias Steinmaurer, Lukas Weseslindtner, Sibylle Madlener, Robert Strassl, Johannes Gojo, Amedeo A. Azizi, Irene Slavc & Andreas Peyrl. (2022) Viral infections in pediatric brain tumor patients treated with targeted therapies. Pediatric Blood & Cancer 70:1.
Crossref
Crossref
Aaron T. Jacobs, Diana Martinez Castaneda-Cruz, Mark M. Rose & Linda Connelly. (2022) Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochemical Pharmacology 204, pages 115209.
Crossref
Crossref
Antonio J. Pagán, Lauren J. Lee, Joy Edwards-Hicks, Cecilia B. Moens, David M. Tobin, Elisabeth M. Busch-Nentwich, Erika L. Pearce & Lalita Ramakrishnan. (2022) mTOR-regulated mitochondrial metabolism limits mycobacterium-induced cytotoxicity. Cell.
Crossref
Crossref
Ivan Noreña, Mario Fernández-Ruiz & José María Aguado. (2022) Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?. Enfermedades infecciosas y microbiologia clinica (English ed.) 40:5, pages 266-272.
Crossref
Crossref
Ivan Noreña, Mario Fernández-Ruiz & José María Aguado. (2022) Is there a real risk of bacterial infection in patients receiving targeted and biological therapies?. Enfermedades Infecciosas y Microbiología Clínica 40:5, pages 266-272.
Crossref
Crossref
Isabel Ruiz-Camps & Juan Aguilar-Company. (2021) Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Therapeutic Advances in Infectious Disease 8, pages 204993612198954.
Crossref
Crossref
Lisa Bodei, Emily Bergsland, Wouter W. de Herder, Diego Ferone, Rodney J. Hicks, Thomas A. Hope, Jolanta Kunikowska, Marianne Pavel, Diane Reidy-Lagunes, Jens Siveke, Jonathan Strosberg, Ulf Dittmer & Ken Herrmann. (2020) Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. Journal of Nuclear Medicine 61:8, pages 1094-1095.
Crossref
Crossref
Isabel Ruiz-Camps & Juan Aguilar-Company. (2020) Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors. Infectious Disease Clinics of North America 34:2, pages 257-270.
Crossref
Crossref
Yutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, Ryunosuke Machida, Akihiko Shimomura, Shigehisa Kitano, Toshio Shimizu & Noboru Yamamoto. (2020) Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials. ESMO Open 5:2, pages e000653.
Crossref
Crossref
Vickie R. Shannon. 2019. Oncologic Critical Care. Oncologic Critical Care
1
27
.
Vickie R. Shannon. 2020. Oncologic Critical Care. Oncologic Critical Care
531
556
.
Vickie R. Shannon. 2019. Oncologic Critical Care. Oncologic Critical Care
1
26
.
M. Reinwald, J.T. Silva, N.J. Mueller, J. Fortún, C. Garzoni, J.W. de Fijter, M. Fernández-Ruiz, P. Grossi & J.M. Aguado. (2018) ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clinical Microbiology and Infection 24, pages S53-S70.
Crossref
Crossref
Sibylle C. Mellinghoff, Jens Panse, Nael Alakel, Gerhard Behre, Dieter Buchheidt, Maximilian Christopeit, Justin Hasenkamp, Michael Kiehl, Michael Koldehoff, Stefan W. Krause, Nicola Lehners, Marie von Lilienfeld-Toal, Annika Y. Löhnert, Georg Maschmeyer, Daniel Teschner, Andrew J. Ullmann, Olaf Penack, Markus Ruhnke, Karin Mayer, Helmut Ostermann, Hans-H. Wolf & Oliver A. Cornely. (2017) Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Annals of Hematology 97:2, pages 197-207.
Crossref
Crossref
Teun van Gelder, Lutz Fischer, Fuad Shihab & Maria Shipkova. (2017) Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. Transplantation Reviews 31:3, pages 151-157.
Crossref
Crossref